Product Images Leflunomide

This text provides statistical data on the ACR 20 Responder at Endpoint for Trial 1 over a 12-month period. It includes percentage values for different treatments (Leflunomide, Methotrexate, Placebo, and Sulfasalazine) and their corresponding scores (s66, 55, a7, P 434, %0, 286, 186).*

This appears to be a graph or chart tracking the percentage of ACR (American College of Rheumatology) responders over time for a clinical trial. The chart is labeled as "Trial 1" and notes that the data is shown using the method of "Last Observation Carried Forward."*

This appears to be a table or chart displaying the results of a study comparing the effects of different medications on functional ability in a specific condition. The text refers to changes in functional ability measured by the HAQ Disability Index over the course of 6 and 12 months. Three medications are listed (Leflunomide, Methotrexate, and Sullasalazine) as well as a placebo. There are numbers and symbols that seem to represent improvement in functional ability at different time points, but it is difficult to interpret without more context.*

This is a medication called Leflunomide, manufactured by Winthrop US, a business of sanofi-aventis U.S. LLC. Each tablet of Leflunomide contains 10mg of the medication. Dosage information can be found in the package insert. It warns to keep out of reach of children and to store it between 15-30°C (59-86°F) and protect it from light. There are three different sizes of tablets, all labeled Leflunomide Tablets with 10TM dosage.*

This is a package insert for Leflunomide tablets. The dosage and administration details can be found in the package insert. The tablets should be stored at 25°C and protected from light. The container used can be larger than the size of the tablets for ease of patient use. The item is manufactured by Sanofi, a French company, and distributed by Sanofi-Aventis in the USA.*